远程医疗服务公司Hims & Hers Health Inc.（HIMS）今日盘中股价大涨13.37%，引起了市场的广泛关注。
消息面上，此次股价大幅上涨主要得益于公司与丹麦制药巨头诺和诺德（Novo Nordisk）达成了一项关键的战略合作协议。根据协议，诺和诺德将通过Hims & Hers的平台销售其广受欢迎的GLP-1减肥药物，包括Ozempic和Wegovy。作为合作的一部分，诺和诺德已同意撤回此前对Hims & Hers提起的专利侵权诉讼，标志着双方从法律争端转向商业伙伴关系。
此项合作显著降低了Hims & Hers此前面临的业务风险，包括产品管线单一性和合规不确定性。花旗集团随后将公司评级从“卖出”上调至“中性”，并大幅将目标价从13.25美元上调至24美元。市场分析认为，该协议被视为公司向更成熟的医疗保健提供商转型的重要一步，增强了投资者对其未来在利润丰厚的减重医疗市场增长潜力的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.